SGLT2i vs placebo
Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
SGLT2i showed no clear difference in stroke (fatal or non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
- Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes onlyOR 1.12 [0.92, 1.36]2 studies · 15266 participantsModerate